137 related articles for article (PubMed ID: 20503262)
1. Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
Djaouti L; Jourdan T; Demizieux L; Chevrot M; Gresti J; Vergès B; Degrace P
Diabetes Metab Res Rev; 2010 May; 26(4):297-305. PubMed ID: 20503262
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.
Deeg MA; Buse JB; Goldberg RB; Kendall DM; Zagar AJ; Jacober SJ; Khan MA; Perez AT; Tan MH;
Diabetes Care; 2007 Oct; 30(10):2458-64. PubMed ID: 17595355
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone, a PPAR-γ agonist, fails to attenuate CLA-induced milk fat depression and hepatic lipid accumulation in lactating mice.
Vyas D; Teter BB; Delmonte P; Erdman RA
Lipids; 2014 Jul; 49(7):641-53. PubMed ID: 24781388
[TBL] [Abstract][Full Text] [Related]
5. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
7. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes.
Rabøl R; Boushel R; Almdal T; Hansen CN; Ploug T; Haugaard SB; Prats C; Madsbad S; Dela F
Diabetes Obes Metab; 2010 Sep; 12(9):806-14. PubMed ID: 20649633
[TBL] [Abstract][Full Text] [Related]
8. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
9. Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
Kus V; Flachs P; Kuda O; Bardova K; Janovska P; Svobodova M; Jilkova ZM; Rossmeisl M; Wang-Sattler R; Yu Z; Illig T; Kopecky J
PLoS One; 2011; 6(11):e27126. PubMed ID: 22073272
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes.
Li Y; Shen Y; Li M; Su D; Xu W; Liang X; Li R
Mol Cell Biochem; 2015 Jul; 405(1-2):233-41. PubMed ID: 25920446
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Guo N; Woeller CF; Feldon SE; Phipps RP
J Biol Chem; 2011 May; 286(21):18856-67. PubMed ID: 21454487
[TBL] [Abstract][Full Text] [Related]
12. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice.
Sun X; Tang Y; Tan X; Li Q; Zhong W; Sun X; Jia W; McClain CJ; Zhou Z
Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(5):G548-57. PubMed ID: 22173916
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones Inhibit Mouse Osteoblastic MC3T3-E1 Cell Proliferation in Part Through the Wnt Signaling Pathway.
Duan M; Zhou B; Zhou X; Yuan G
J Investig Med; 2015 Jun; 63(5):758-64. PubMed ID: 25756249
[TBL] [Abstract][Full Text] [Related]
14. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
15. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
16. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.
Lecka-Czernik B; Ackert-Bicknell C; Adamo ML; Marmolejos V; Churchill GA; Shockley KR; Reid IR; Grey A; Rosen CJ
Endocrinology; 2007 Feb; 148(2):903-11. PubMed ID: 17122083
[TBL] [Abstract][Full Text] [Related]
17. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner.
Al-Alem L; Southard RC; Kilgore MW; Curry TE
PLoS One; 2011 Jan; 6(1):e16179. PubMed ID: 21283708
[TBL] [Abstract][Full Text] [Related]
18. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.
Wang S; Goodspeed L; Turk KE; Houston B; den Hartigh LJ
Endocrinology; 2017 Sep; 158(9):2848-2859. PubMed ID: 28651330
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.
Chu Y; Lund DD; Weiss RM; Brooks RM; Doshi H; Hajj GP; Sigmund CD; Heistad DD
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):523-32. PubMed ID: 23288158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
